Dry Powder Inhalers (DPI)

From Milk to Medicine: 100 Years of Pharmaceutical Lactose continuous improvement For more than a century, lactose has quietly shaped...

Abstract The therapeutic landscape for biologics is rapidly transitioning from intravenous (IV) to subcutaneous (SC) administration, offering significant benefits in...

Abstract Background/Objectives: Cannabidiol (CBD) has emerged as a potential therapeutic agent for respiratory disorders, including asthma and chronic obstructive pulmonary...

Abstract Background/Objectives: This study aims to investigate the underexplored impact of cap- sule type on the performances of capsule-based dry...

Abstract Background/Objectives: Accurate determination of active pharmaceutical ingredient (API) particle size within dry powder inhaler (DPI) formulations is essential for ensuring...

Abstract Background/Objectives: The development of dry powder formulations for pulmonary delivery of therapeutic antibodies requires careful stabilization strategies to preserve...

Abstract Environmental relative humidity (RH) and temperature (T) are known to be promoters of physicochemical changes in pharmaceutical grade lactose,...

Abstract Background/Objectives: Reproducible evaluation of aerosol dispersibility remains a key challenge in the development of dry powder inhalers (DPIs), where small...

Abstract Despite being subject to a multitude of investigations, the effect of carrier particle size on the performance of adhesive...

Abstract Lower respiratory tract infections (LRTIs) constitute the fourth leading cause of mortality worldwide, resulting in over two million deaths...